"Preliminary Guidelines for the Use of Tocilizumab in COVID-19 Pneumonia" "Preliminary Guidelines for the Use of Tocilizumab in COVID-19 Pneumonia"

Abstract

We consider it important to make known to the scientific community, the preliminary guidelines for the use of tocilizumab in pneumonia due to COVID-19, it is a recombinant monoclonal antibody directed against the soluble and membrane-bound alpha receptor of IL-6.

Although it has not yet been incorporated into the treatment guidelines of the World Health Organization and has not been approved by the ANMAT in our country for the treatment of COVID-19, due to the additional benefits to the use of dexamethasone that it could have tocilizumab, reducing mortality (particularly in the most serious cases or those with a high risk of progression) and relieving stress on health services (by reducing the time of organic support and hospital stay), we consider it appropriate to make preliminary suggestions for its use in patients hospitalized for COVID-19 in our environment